SARS-CoV-2 Testing

Scalable Testing for Respiratory Viral RNA Detection

The SARS-CoV-2 pandemic has created an enormous challenge for laboratories and communities worldwide. Currently, laboratories require cost-effective and rapid solutions to track the key SARS-CoV-2 variants currently in circulation, globally. While sequencing-based technologies are commonly used, they are highly complex, expensive, and have a long turnaround time.

To meet these challenges, Agena Bioscience^® has developed the MassARRAY^® SARS-CoV-2 Variant Panel (RUO), the MassARRAY SARS-CoV-2 Panel (EUA, CE-IVD), and the MassARRAY SARS-CoV-2/Flu Panel (RUO). These panels enable accurate, high-throughput, and low-cost detection of SARS-CoV-2, dominant SARS-CoV-2 variants, and influenza RNA.

• MAXIMIZE THROUGHPUT – Process up to thousands of samples in a workday with a single MassARRAY System.
• ENSURE ACCURATE DETECTION – Robust assay design with multiple SARS-CoV-2 targets and pan-assays for influenza A and influenza B.
• SAVE TIME & MONEY – Low-cost reagents and automated results reporting saves lab resources.
• SECURE RELIABLE SUPPLY – Immediate availability of instruments and reagents.

Get Started Now

The MassARRAY SARS-CoV-2 Variant Panel is available for Research Use Only.

The MassARRAY SARS-CoV-2 Panel is available for in vitro diagnostic use under Emergency Use Authorization (EUA) from the U.S. FDA and is CE-IVD marked in Europe.

The MassARRAY SARS-CoV-2/Flu Panel is available for Research Use Only.